Global Precision Oncology Market, Valued at USD 118.8 Bn, to Reach USD 230.04 Bn by 2032 at 9.9% CAGR - AI-Driven Cancer Care Fuels Rapid Growth

Market Overview

The Global Precision Oncology Market was valued at USD 118.8 billion in 2025 and is forecast to reach USD 230.04 billion by 2032, growing at a 9.9% CAGR during 2026-2032, according to Maximize Market Research. The market covers oncology solutions that analyze tumor molecular profiles, identify actionable genetic alterations, and support individualized cancer treatment decisions.

Precision oncology is becoming central to modern cancer care because it links diagnostics, biomarkers, next-generation sequencing, targeted therapy, immunotherapy, and treatment monitoring into one patient-specific clinical pathway. MMR notes that growing cancer prevalence, genomic sequencing advances, biomarker discovery, and government-backed cancer research initiatives are key demand drivers.

The market's momentum is also tied to the shift from broad chemotherapy-led models toward molecularly guided therapy selection. As genomic testing becomes more integrated with hospital oncology workflows, drug development, companion diagnostics, and clinical trial design, precision oncology is positioned as a strategic growth area for pharmaceutical companies, diagnostic laboratories, healthcare data companies, and cancer care networks.

Download a Free Sample Report Today: https://www.maximizemarketresearch.com/request-sample/188401/

Key Growth Drivers Fueling the Global Precision Oncology Market

Rising cancer burden and treatment personalization: MMR identifies rising global cancer prevalence as a major driver of demand. Precision oncology helps tailor treatment to the molecular characteristics of individual tumors, supporting improved treatment selection and reducing dependence on one-size-fits-all cancer care.

Advances in genomic sequencing: Continuous improvements in genomic sequencing technology are accelerating precision oncology adoption. Next-generation sequencing enables comprehensive genomic profiling, biomarker identification, and the detection of actionable cancer mutations.

Growth in targeted therapies and immunotherapy: MMR highlights immunotherapy, gene editing, and molecularly targeted treatments as technologies positively influencing the market. Targeted therapies, immunotherapies, and molecularly guided drugs are increasingly used to improve effectiveness and reduce side effects compared with conventional treatment approaches.

Government support for cancer research: MMR notes support from government organizations, including U.S. initiatives such as Cancer Moonshot, the Precision Medicine Initiative, and the National Cancer Institute, along with European Union research programs. These initiatives strengthen research pipelines, clinical adoption, and translational oncology infrastructure.

AI-enabled treatment optimization: MMR identifies AI as a crucial market trend, with AI tools supporting biomarker discovery, drug development, treatment optimization, predictive analysis, and the interpretation of complex genomic datasets.

Market Segmentation - By Type, Application & End-Use

MMR segments the Global Precision Oncology Market across product type, cancer type, biomarker type, therapy type, application, and end user. Publicly available MMR summary data does not disclose segment percentage shares for each category; only dominant segments are identified where stated.

Product Type: Diagnostics; Therapeutics - dominant segment in 2025.

Cancer Type: Breast Cancer - dominant segment in 2025; Lung Cancer; Cervical Cancer; Colorectal Cancer; Prostate Cancer; Others.

Biomarker Type: Genomics; Transcriptomics; Proteomics; Epigenomics; Pharmacogenomics; Others.

Therapy Type: Targeted Therapy; Immunotherapy; Hormone Therapy; Chemotherapy; Radiotherapy; Others.

Application: Diagnostics; Prognostics; Therapeutics; Drug Development & Clinical Trials; Monitoring & Recurrence Detection; Others.

End User: Pharmaceutical & Biotechnology Companies; Diagnostic Centres; Healthcare Data Companies; Others.

The therapeutics segment leads because it directly converts molecular insights into personalized cancer treatment. MMR states that biomarker-based drugs, regulatory approvals for targeted oncology therapies, pharmaceutical R&D investment, and the growing use of genomic testing to guide therapy selection have strengthened this segment. Breast cancer leads the cancer-type segment due to high prevalence, strong research activity, broad use of genetic testing, biomarker identification, companion diagnostics, and targeted therapy.

Regional Analysis - Where Is the Global Precision Oncology Market Growing Fastest?

United States
The United States leads the global precision oncology market due to advanced healthcare infrastructure and substantial research and development investment, according to MMR. MMR also states that the U.S. has nearly 44% market share, supported by heavy infrastructure investment and major companies such as Pfizer and Johnson & Johnson.

United Kingdom
MMR identifies Europe as the second-highest market after the U.S., with the United Kingdom contributing through technological progress and the presence of AstraZeneca. The UK market benefits from Europe's broader adoption of molecular diagnostics and research investment.

Germany
Germany is highlighted by MMR as a technologically advanced European market and is linked to Merck in the regional competitive landscape. The country is positioned within Europe's sustained precision oncology growth, supported by molecular diagnostics adoption and research capacity.

Japan
MMR states that Asia Pacific is growing after major investment into the market and identifies Japan, China, and India as emerging leaders. Japan's opportunity is therefore tied to Asia Pacific's broader investment momentum and expanding precision oncology adoption.

South Korea
MMR includes South Korea within the Asia Pacific precision oncology market coverage. The public MMR summary does not disclose a separate South Korea market size or share, so no standalone country-level statistic is assigned here.

China
MMR identifies China as one of the Asia Pacific leaders and states that the country has a large market share within the industry. The report links China's precision oncology opportunity to rising population, patient growth, and the region's broader market expansion.

India
MMR states that India has emerged as a leader in Asia Pacific and that the broader region is growing after major market investment. MMR also notes that emerging markets such as India and Japan are helping diversify the precision oncology market.

North America is the dominant region, led by the United States, while Asia Pacific shows the highest market growth outlook in MMR's regional commentary. The United States remains the top investment hotspot because MMR assigns it nearly 44% market share and links its leadership to infrastructure and R&D investment.

Competitive Landscape - Leading Companies in the Global Precision Oncology Market

Illumina, Inc. - MMR lists Illumina among the key competitors and also cites the company's role in North America's strong market presence. MMR's recent developments section states that Illumina announced advancements in next-generation sequencing platforms for precision oncology clinical adoption in January 2026.

Thermo Fisher Scientific, Inc. - MMR identifies Thermo Fisher Scientific as a key player and references it in the North American competitive base. Its position aligns with MMR's emphasis on genomic sequencing, laboratory capability, and molecular diagnostics as market growth factors.

Agilent Technologies, Inc. - Agilent is listed by MMR among the key U.S.-based competitors in the precision oncology market. The company's relevance sits within the diagnostics, biomarker, and laboratory workflow ecosystem described in the MMR segmentation.

Invitae Corporation - MMR includes Invitae Corporation in the strategic competitor profile list. Its listing reflects the market's dependence on genetic testing, genomics, and patient-specific cancer profiling.

NeoGenomics Laboratories, Inc. - NeoGenomics is named by MMR as a key competitor. The company is positioned within a market where diagnostic centres, genomic testing, and oncology laboratory capabilities are central to adoption.

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report:https://www.maximizemarketresearch.com/market-report/precision-oncology-market/188401/

Recent Developments & Strategic Moves

Illumina, January 2026: MMR states that Illumina announced advancements in NGS platforms aimed at expanding precision oncology adoption in clinical settings and improving identification of cancer-related mutations.

Guardant Health, October 2025: MMR reports progress in adoption of Guardant Health liquid biopsy tests for early cancer detection and treatment monitoring using circulating tumor DNA.

Illumina and Labcorp, March 2026: The companies expanded collaboration to broaden access to precision oncology testing through NGS-based solutions, distributed test offerings, evidence generation, and tissue and liquid biopsy assays.

Guardant Health and Pfizer, April 2025: Guardant announced a strategic collaboration with Pfizer to support development and commercialization of oncology therapies using the Guardant Infinity smart liquid biopsy platform.
NCI, July 2026: The National Cancer Institute announced a workshop focused on moving functional precision oncology from laboratory research into clinical practice.

AI & Digital Transformation Impact on Global Precision Oncology Market

AI is changing the Global Precision Oncology Market by improving how complex genomic and clinical datasets are interpreted. MMR states that AI-driven tools can support biomarker discovery, drug development, treatment optimization, predictive analysis, and algorithms that predict how cancer cells may respond to treatment.

Digital transformation is also reshaping liquid biopsy, pathology, and multi-omics workflows. Guardant Health, for example, has highlighted liquid biopsy applications enabled by multiomic profiling and an AI learning engine that identifies patterns and refines predictions. Imagene AI and Sheba Medical Center also announced a precision oncology intelligence alliance using real-world data, multimodal AI, pathology images, omics, and longitudinal clinical records to support cancer research and personalized care.

Future Outlook - Investment Opportunities & Emerging Trends

The future of the Global Precision Oncology Market is defined by deeper integration of AI, gene editing, combination therapies, immunotherapy, genomic sequencing, companion diagnostics, liquid biopsy, and biomarker-guided drug development. MMR states that AI, gene editing technologies, and combination therapies will dictate the market's future trend, while Asia Pacific is expected to rise due to major investments and emerging leadership from China, Japan, and India. For investors, the strongest strategic zones are U.S.-led infrastructure and R&D, European molecular diagnostics adoption, and Asia Pacific's high-growth cancer care modernization.

Expert Commentary

"According to [Komal Patil ], Research Manager at Maximize Market Research, 'The Global Precision Oncology Market is moving from USD 118.8 billion in 2025 toward USD 230.04 billion by 2032 at a 9.9% CAGR, supported by genomic sequencing, biomarker-led therapeutics, and AI-enabled treatment optimization. Investment momentum is strongest where oncology infrastructure, molecular diagnostics, and data-driven treatment planning converge, with North America leading and Asia Pacific emerging as the fastest-growth region."

For additional reports on related topics, visit our website:

Agoraphobia Market ➤ https://www.maximizemarketresearch.com/market-report/agoraphobia-market/222800/

Whole Exome Sequencing Market ➤
https://www.maximizemarketresearch.com/market-report/whole-exome-sequencing-market/220646/

Pseudomonas Putida Market ➤
https://www.maximizemarketresearch.com/market-report/pseudomonas-putida-market/213422/

2nd Floor, Navale IT Park Phase 3
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India
+91 9607365656
sales@maximizemarketresearch.com

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

This release was published on openPR.